They occupy entirely different evidence tiers: Cerebrolysin has decades of clinical trial data and systematic reviews, while Dihexa has only preclinical animal studies with questioned integrity
NAD+ struggles with absorption through the digestive system and can't easily cross cell membranes [3]
Most BPC-157 preclinical work uses dosages around 10 mcg/kg administered intraperitoneally or subcutaneously in rodents, with study durations ranging from single administration to 14-day periods
The medicine encourages the special area of the brain to make more growth hormone
He said many peptides are naturally occurring compounds that lack the patent protections needed to justify expensive clinical development programs
To date, no single bacterium, virus, fungus, or fastidious microorganism has been isolated as an etiologic factor in IC/BPS